Latest Breaking News On - Medical oncology virtual - Page 1 : comparemela.com

Extended Imatinib Maintenance Boosts Disease-Free Survival in High-Risk GIST

Extended Imatinib Maintenance Boosts Disease-Free Survival in High-Risk GIST
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.

Charles bankheadHans gelderblomScandinavian sarcoma groupUniversity claude bernardLeiden university medical centerEuropean society for medical oncologyEuropean society for medical oncology virtual plenaryJean yves blayEuropean societyMedical oncologyMedpage todayMedical oncology virtual

Treatment Breakthroughs: Immunotherapy Comes for Advanced Endometrial Cancer

Treatments for advanced endometrial cancer have progressed and improved with the use of immunotherapy with chemotherapy.

United statesMiami beachFlorida international universityMemorial sloan kettering cancer centerNew yorkBrian slomovitzVicky makkerLindar duskaValerie smithRamezn eskanderUniversity of virginiaEuropean society for medical oncology virtual plenaryDrug administrationNational cancer instituteUniversity of california san diegoEndometrial cancer action network for african

Merck Announces First-Quarter 2023 Financial Results

First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines Total Worldwide Sales Were $14.5 Billion, a Decrease of 9%. | April 27, 2023

United statesAdempas verquvoRobertm davisMerck co incWorld health organization groupOncology programGilead sciencesSichuan kelun pharmaceutical co ltdNet income attributable to merck co incCardiovascular programExchange commissionDrug administrationAmerican association for cancer research annual meetingAmerican college of cardiologyImago biosciences incWorld heart federation congress

Merck & Co (MRK) Q1 2022 Earnings Call Transcript

MRK earnings call for the period ending March 31, 2022.

United statesAndrew baumEliav barrDaina grayboschChris shibutaniCarter gouldRob davisPeter dannenbaumCaroline litchfieldLouise chen cantor fitzgeraldRoy baynesAndrew baum citiSeamus fernandez guggenheimMara goldsteinSeamus fernandezMara goldstein mizuho

Lynparza® significantly reduces risk of death in early breast cancer patients

Lynparza® (olaparib) is the first PARP inhibitor to demonstrate overall survival benefit in early breast cancer, according to new data.

United statesUnited kingdomCity ofAndrew tuttSusan galbraithKing college londonEuropean society for medical oncology virtual plenaryDrug administrationFrontier science technology research foundationAmerican society of clinical oncology annual meetingBreast international groupInstitute of cancer researchOlympia phaseEuropean societyMedical oncology virtualFrontier science